GlobeNewswire Press

  1. Penwest Pharmaceuticals Agrees To Be Acquired By Endo Pharmaceuticals For $5.00 Per Share In Cash 8/10/2010
    Penwest Pharmaceuticals Co. today announced that it has entered into a merger agreement under which its long-time partner in the development and commercialization of Opana® ER, Endo Pharmaceuticals, has agreed to acquire all of the common stock of Penwest for $5.00 per share in cash.
  2. XOMA Receives $750,000 Milestone Payment From AVEO Pharmaceuticals 7/26/2010
    XOMA Ltd. /quotes/comstock/15*!xoma/quotes/nls/xoma (XOMA 0.34, +0.01, +1.99%) , a leader in the discovery and development of therapeutic antibodies, announced receipt of a $750,000 milestone payment under its collaboration with AVEO Pharmaceuticals, Inc.
  3. NovaBay Pharmaceuticals' Non-Antibiotic Anti-Infective Successful In Phase 2 Skin Infection Trial 7/22/2010
    NovaBay Pharmaceuticals, Inc. (NYSE Amex:NBY) today announced that its lead product candidate was safe and efficacious against the highly contagious skin infection impetigo in a Phase 2a proof-of-concept clinical trial.
  4. Tongli Pharmaceuticals (USA) Inc. Has Three Products Included In Essential Drug List 7/22/2010
    Tongli Pharmaceuticals (USA) Inc. (OTCBB:TGLP), announced the following three of its products have been included in China's Essential Drug List ("EDL"): Calcium Gluconate Oral Liquid, Metformin Hydrochloride Tablets, Clindamycin Hydrochloride.
  5. ATMI® Adds Ultra-Clean 2-D And 3-D Bioprocess Vessels To Integrity™ Single-Use Product Line 7/8/2010
    ATMI, Inc. today unveiled an important extension to its Integrity™ product line for the biopharmaceutical and biotechnology industries with the introduction of a new range of single-use bioprocess vessels (BPVs).
  6. Myriad Pharmaceuticals Formally Adopts Its Name Change To Myrexis, Inc. Effective July 1, 2010 7/1/2010
    Effective July 1, Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX) will change its name to Myrexis, Inc. The name change was previously approved by the Company's shareholders at a special meeting held on April 22, 2010. The Company's Common Stock will continue to trade on the Nasdaq Global Market stock exchange under the symbol MYRX.
  7. Infinity Initiates Second Clinical Trial Of IPI-493, Its Oral Hsp90 Chaperone Inhibitor 6/29/2010
    Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative drug discovery and development company, today announced that patients are being enrolled in a Phase 1 clinical trial evaluating IPI-493 in patients with advanced hematologic malignancies.
  8. Preclinical Results With XOMA 052 In Type 2 Diabetes Presented At American Diabetes Association 70th Scientific Sessions 6/29/2010
    XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, will be presenting new preclinical data in an animal model of Type 2 diabetes in which its anti-inflammatory therapeutic antibody candidate, XOMA 052, was used as monotherapy and in combination with the marketed anti-diabetic drugs exendin-4 (Byetta®) or sitagliptin (Januvia®).
  9. Pain Therapeutics Modifies Strategic Alliance For REMOXY® In Europe 6/29/2010
    Pain Therapeutics, Inc. (Nasdaq:PTIE) announced today a modification of its strategic alliance with King Pharmaceuticals, Inc. (NYSE:KG) for REMOXY outside the U.S. The move signals a desire to target Europe's small and growing market for strong pain medications.
  10. Elite Pharmaceuticals Announces Acquisition Of Generic Hydromorphone Product 5/27/2010
    Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) announced today the acquisition of a currently approved Abbreviated New Drug Application (ANDA) for hydromorphone hydrochloride 8 mg tablets from Mikah Pharma LLC.